Page Therapeutics
Targeting cell-cell adhesion in cancer
- Employees
- 1–10
- Founded
- 2022
- Business Model
- B2B
- Website
- pagetherapeutics.com
- Rounds
- 1
About
PAGE Therapeutics is a platform-based oncology drug development company whose mission is to discover and commercialize compounds that disrupt cell-cell adhesion in cancer cells to improve and prolong the lives of cancer patients. The company targets circulating tumor cell clusters, multicellular groupings held together by adhesion molecules that are highly efficient pioneers of metastasis and mark patients with poor prognosis. PAGE is developing new chemistry with cluster-dissolution activity to change how metastatic spread is treated.
Summary
Page Therapeutics is a Biotech company, founded in 2022. Investors include XGEN Venture and Claris Ventures.
Tech & App Stack
5 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Integrated biopharmaceutical solutions company
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/page-therapeutics"><img src="https://indexed.vc/api/badge/company/page-therapeutics" alt="Page Therapeutics on Indexed.vc" width="260" height="76" /></a>